Skip to main content
. 2022 Dec 29;9(1):e000732. doi: 10.1136/lupus-2022-000732

Table 2.

IF-ANA staining patterns (HEp-2 cells) according to the ICAP nomenclature for the three diseases and as well as for HBDs

ICAP staining pattern SLE: discovery cohort (n=282) pSS (n=116) SSc (n=57) HBDs (n=236)
AC-0 (negative) 72 (25.5) 29 (25.0) 2 (3.5) 211 (89.4)
AC-1 (homogeneous) 104 (36.9) 30 (25.9) 8 (14.0) 9 (3.8)
AC-3 (centromere) 2 (0.7) 1 (0.9) 12 (21.1) 0 (0)
AC-4 (speckled) 41 (14.5) 36 (31.0) 17 (29.8) 6 (2.5)
AC-6 (multiple nuclear dots) 2 (0.7) 0 (0) 0 (0) 1 (0.4)
AC-8 (nucleolar) 10 (3.5) 1 (0.9) 1 (1.8) 4 (1.7)
AC-1+4 39 (13.8) 18 (15.5) 7 (12.3) 5 (2.1)
AC-1+4+8 2 (0.7) 0 (0) 2 (3.5) 0 (0)
AC-1+8 9 (3.2) 1 (0.9) 0 (0) 0 (0)
AC-4+7 (speckled+few nuclear dots) 0 (0) 0 (0) 1 (1.8) 0 (0)
AC-4+8 1 (0.35) 0 (0) 7 (12.3) 0 (0)

Percentages are given in parentheses.

HBDs, healthy blood donors; ICAP, International Consensus on ANA Patterns; IF-ANA, ANA detected with immunofluorescence microscopy; pSS, primary Sjögren’s syndrome; SSc, systemic sclerosis.